Literature DB >> 4059720

Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer.

R J Marshall, E M Chisholm.   

Abstract

We discuss the use of the trichotomous logistic model to discriminate between patients with gastrointestinal (GI) cancer, patients with benign GI disease and 'normal' subjects, using symptoms and the concentrations of some serum proteins that are potentially indicative of malignancy as covariates. A parsimonious model can be obtained by invoking an indistinguishability hypothesis which is appropriate when a covariate is considered to have no predictive value between categories. It is shown that the polychotomous model can be re-parameterised under the null hypothesis to give a 'reduced form', which can be fitted by maximum likelihood. The validity of the use of the same methods for retrospective sampling is discussed. The approach is illustrated by the development of a logistic model to identify symptomatic and asymptomatic subjects with a high risk of GI cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4059720     DOI: 10.1002/sim.4780040313

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  28 in total

1.  Plasma carotenoids and risk of breast cancer over 20 y of follow-up.

Authors:  A Heather Eliassen; Xiaomei Liao; Bernard Rosner; Rulla M Tamimi; Shelley S Tworoger; Susan E Hankinson
Journal:  Am J Clin Nutr       Date:  2015-04-15       Impact factor: 7.045

2.  Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression.

Authors:  Holly R Harris; Megan S Rice; Amy L Shafrir; Elizabeth M Poole; Mamta Gupta; Jonathan L Hecht; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-13       Impact factor: 4.254

3.  Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.

Authors:  Holly R Harris; Ana Babic; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; Catherine M Phelan; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

4.  Premenopausal plasma carotenoids, fluorescent oxidation products, and subsequent breast cancer risk in the nurses' health studies.

Authors:  Julia S Sisti; Sara Lindström; Peter Kraft; Rulla M Tamimi; Bernard A Rosner; Tianying Wu; Walter C Willett; A Heather Eliassen
Journal:  Breast Cancer Res Treat       Date:  2015-04-28       Impact factor: 4.872

5.  Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.

Authors:  H R Harris; L J Titus; D W Cramer; K L Terry
Journal:  Int J Cancer       Date:  2016-10-06       Impact factor: 7.396

6.  Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies.

Authors:  A Heather Eliassen; Sara J Hendrickson; Louise A Brinton; Julie E Buring; Hannia Campos; Qi Dai; Joanne F Dorgan; Adrian A Franke; Yu-tang Gao; Marc T Goodman; Göran Hallmans; Kathy J Helzlsouer; Judy Hoffman-Bolton; Kerstin Hultén; Howard D Sesso; Anne L Sowell; Rulla M Tamimi; Paolo Toniolo; Lynne R Wilkens; Anna Winkvist; Anne Zeleniuch-Jacquotte; Wei Zheng; Susan E Hankinson
Journal:  J Natl Cancer Inst       Date:  2012-12-06       Impact factor: 13.506

7.  Evaluation of risk factors for cataract types in a competing risks framework.

Authors:  Robert J Glynn; Bernard Rosner; William G Christen
Journal:  Ophthalmic Epidemiol       Date:  2009 Mar-Apr       Impact factor: 1.648

8.  Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up.

Authors:  Xuehong Zhang; Shelley S Tworoger; A Heather Eliassen; Susan E Hankinson
Journal:  Breast Cancer Res Treat       Date:  2013-01-03       Impact factor: 4.872

9.  Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women.

Authors:  A Heather Eliassen; Stacey A Missmer; Shelley S Tworoger; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

10.  Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses' Health Study II.

Authors:  Jun Wang; A Heather Eliassen; Donna Spiegelman; Walter C Willett; Susan E Hankinson
Journal:  Cancer Causes Control       Date:  2014-04-20       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.